Acute myeloid leukemia (AML)
- Treatment is genetics-, age- + fitness-driven
- Fit patients often receive intensive induction
- Older/unfit patients often use azacitidine + venetoclax
- Add targeted drug for actionable mutations
- Consolidation ± allogeneic transplant follows risk
- APL is treated differently—recognize it urgently
Use at a glance
- Treatment is genetics-, age- + fitness-driven
Practical pearls
- Fit patients often receive intensive induction
Treatment options
- Older/unfit patients often use azacitidine + venetoclax
- Add targeted drug for actionable mutations
Monitoring / follow-up
- Consolidation ± allogeneic transplant follows risk
- APL is treated differently—recognize it urgently
Self-check
- What guides AML treatment selection?
Genetics, age + fitness. - What do older or unfit AML patients often receive?
Azacitidine + venetoclax.
Drugs used for this (1)
All clinical uses · Open Acute myeloid leukemia (AML) in the interactive console ↗